SCHEMBL4436745

SCHEMBL4436745

CCCCC(C(=O)N[C@@H](CC(=O)O)c1cccc(OCCC)c1)n1cc(C)cc(Cc2ccccc2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
CASP1 P29466 2/20 0.39
FPR1 P21462 2/20 0.39
ALDH1A1 P00352 2/20 0.38
PTGES O14684 1/20 0.37
ALOX5 P09917 1/20 0.37
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
GPR88 Q9GZN0 3/20 0.36
CYSLTR2 Q9NS75 3/20 0.35
CYSLTR1 Q9Y271 3/20 0.35
GAA P10253 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4436912 0.98 SMN1; SMN2 (0.40) SMN1; SMN2CASP1FPR1ALDH1A1PTGES
SCHEMBL4426307 0.95 CASP1 (0.39) SMN1; SMN2CASP1FPR1ALDH1A1
SCHEMBL4436753 0.93 FPR1 (0.42) SMN1; SMN2CASP1FPR1ALDH1A1PTGES
SCHEMBL4434290 0.92 FPR1 (0.39) SMN1; SMN2CASP1FPR1GPR88
SCHEMBL4427187 0.90 MMP2 (0.38) SMN1; SMN2CASP1FPR1
SCHEMBL7429087 0.90 MMP2 (0.38) SMN1; SMN2CASP1FPR1
SCHEMBL4427933 0.90 ITGB3 (0.42) CASP1FPR1
SCHEMBL4435231 0.89 CASP1 (0.38) CASP1FPR1PPARG
SCHEMBL7431479 0.89 CASP1 (0.38) CASP1FPR1PPARG
SCHEMBL4429239 0.89 CASP1 (0.38) CASP1FPR1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1213288-B1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC (US) 2009-01-14 EP disclosed
EP-1213288-A1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-06-12 EP disclosed